K M Eggers1, M Hjort1,2, T Baron1,2, T Jernberg3, A M Nordenskjöld4, P Tornvall5, B Lindahl1,2. 1. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 2. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 3. Department of Clinical Sciences, Cardiology, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. 4. Faculty of Health, Department of Cardiology, Örebro University, Örebro, Sweden. 5. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, Stockholm, Sweden.
Abstract
BACKGROUND: Myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is receiving increasing interest as a prognostically adverse entity distinct from myocardial infarction with significant coronary artery disease (MI-CAD). However, data are still limited regarding long-term cardiovascular morbidity and cause-specific mortality in MINOCA. METHODS: This is a registry-based cohort study using data from patients admitted to Swedish coronary care units. We investigated various nonfatal outcomes (recurrent MI, hospitalization for heart failure or stroke) and fatal outcomes (cardiovascular, respiratory or cancer-related mortality) in 4069 patients without apparent acute cardiovascular disease, used as non-MI controls, 7266 patients with first-time MINOCA and 69 267 patients with first-time MI-CAD. RESULTS: Almost all event rates (median follow-up 3.8 years) increased in a stepwise fashion across the three cohorts [rates of major adverse events (MAE; composite of all-cause mortality, recurrent MI, hospitalization for heart failure or stroke): n = 268 (6.6%), n = 1563 (21.5%), n = 17 777 (25.7%), respectively]. Compared to non-MI controls, MINOCA patients had an adjusted hazard ratio (HR) of 2.12 (95% confidence interval 1.84-2.43) regarding MAE. MINOCA patients had a substantial risk of cardiovascular mortality and the highest numerical risks of respiratory and cancer-related mortality. Male sex, previous heart failure and chronic obstructive pulmonary disease had a stronger prognostic impact in MINOCA than in MI-CAD. Female MINOCA patients with atrial fibrillation were at particular risk. CONCLUSIONS: Patients with first-time MINOCA have a considerable risk of adverse events. This stresses the need for a comprehensive search of the cause of MINOCA, thorough treatment of underlying disease triggers and close follow-up.
BACKGROUND:Myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is receiving increasing interest as a prognostically adverse entity distinct from myocardial infarction with significant coronary artery disease (MI-CAD). However, data are still limited regarding long-term cardiovascular morbidity and cause-specific mortality in MINOCA. METHODS: This is a registry-based cohort study using data from patients admitted to Swedish coronary care units. We investigated various nonfatal outcomes (recurrent MI, hospitalization for heart failure or stroke) and fatal outcomes (cardiovascular, respiratory or cancer-related mortality) in 4069 patients without apparent acute cardiovascular disease, used as non-MI controls, 7266 patients with first-time MINOCA and 69 267 patients with first-time MI-CAD. RESULTS: Almost all event rates (median follow-up 3.8 years) increased in a stepwise fashion across the three cohorts [rates of major adverse events (MAE; composite of all-cause mortality, recurrent MI, hospitalization for heart failure or stroke): n = 268 (6.6%), n = 1563 (21.5%), n = 17 777 (25.7%), respectively]. Compared to non-MI controls, MINOCA patients had an adjusted hazard ratio (HR) of 2.12 (95% confidence interval 1.84-2.43) regarding MAE. MINOCA patients had a substantial risk of cardiovascular mortality and the highest numerical risks of respiratory and cancer-related mortality. Male sex, previous heart failure and chronic obstructive pulmonary disease had a stronger prognostic impact in MINOCA than in MI-CAD. Female MINOCA patients with atrial fibrillation were at particular risk. CONCLUSIONS:Patients with first-time MINOCA have a considerable risk of adverse events. This stresses the need for a comprehensive search of the cause of MINOCA, thorough treatment of underlying disease triggers and close follow-up.
Authors: Nathan J Reinert; Bansri M Patel; Qasem N AlShaer; Liwen Wu; Stephen Wisniewski; Eric S Hager; Mitchell R Dyer; Parthasarathy D Thirumala Journal: Neurologist Date: 2021-11-30 Impact factor: 1.398
Authors: Guoqing Yin; Lu Liu; Abdul-Quddus Mohammed; Rong Jiang; Fuad A Abdu; Wenliang Che Journal: Int J Med Sci Date: 2022-05-27 Impact factor: 3.642
Authors: Nousjka P A Vranken; Tobias F S Pustjens; Evelien Kolkman; Renicus S Hermanides; Sebastiaan C A M Bekkers; Martijn W Smulders; Yvonne J M van Cauteren; Jordi Heijman; Saman Rasoul; Jan P Ottervanger; Arnoud W J van 't Hof Journal: Int J Cardiol Heart Vasc Date: 2020-07-01
Authors: Lucas Lentini Herling de Oliveira; Vinícius Machado Correia; Pedro Felipe Gomes Nicz; Paulo Rogério Soares; Thiago Luis Scudeler Journal: J Clin Med Date: 2022-09-20 Impact factor: 4.964
Authors: Kai M Eggers; Tomasz Baron; Marcus Hjort; Anna M Nordenskjöld; Per Tornvall; Bertil Lindahl Journal: J Am Heart Assoc Date: 2021-09-02 Impact factor: 5.501